<DOC>
	<DOC>NCT02981225</DOC>
	<brief_summary>The purpose of the study is to describe, over 6 weeks, the evolution of depressive symptoms in patients with mild to moderate major depression in a strategy with Phytostandard® Rhodiola-Saffron supplementation</brief_summary>
	<brief_title>Descriptive Study of a Management Strategy for Mild to Moderate Major Depression: Combination of Rhodiola and Saffron Extracts.</brief_title>
	<detailed_description>For this study, 52 patients are going to be included. They will have a supplementation of Phytostandard® rhodiola/saffron, from 2 tablets per day during 42 days. on the one hand, during the two visits (inclusion and follow-up), the investigator completes the Hamilton Depression Scale (HAM-D) and the Clinical Global Impression (CGI). During the inclusion visit, he completes with his patient CIM-10 for depression diagnostic. on the other hand, patients complete HAD 4 times : just after the inclusion visit, at day 14, at day 28 and just before the follow-up visit. He completes the Patient Global Impression too at each time.</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<criteria>Suffering from mild to moderate depression as defined in CIM10 Having a score on the HAMD questionnaire between 8 and 18 Having agreed to participate at the study after being informed by the investigator Depressive patients already under medication or discontinuation of medication less than a month ago Patients with severe depression as defined in CIM10 or HAMD&gt; 18 Patients considered at risk: attempted suicide or suicidal (observed by the investigator or Hamilton item 3 score&gt; 2) Patients with psychiatric disorders: schizophrenia, bipolarity, addiction (drugs, alcohol ...), etc. Patient with severe disease (cancer, kidney or heart disease) or patient with a contraindication for taking the product (patient under antihypertensive ...) Patients using agents containing piperine or St. John's wort (interactions) Pregnant or breastfeeding patients Patients who do not wish to complement Phytostandard® Rhodiola Saffron. Patients who do not wish to participate in the study. Patients unable to understand the ins and outs of the study (mental incapacity, language barrier).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>